Balaji Gandhi Sells 8,009 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 8,009 shares of Phreesia stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $136,233.09. Following the sale, the chief financial officer owned 156,231 shares of the company’s stock, valued at $2,657,489.31. The trade was a 4.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Friday, October 17th, Balaji Gandhi sold 885 shares of Phreesia stock. The stock was sold at an average price of $22.36, for a total transaction of $19,788.60.

Phreesia Trading Down 0.6%

Shares of NYSE:PHR traded down $0.10 during trading on Monday, reaching $17.14. 760,277 shares of the company were exchanged, compared to its average volume of 1,018,096. The business’s fifty day simple moving average is $18.95 and its 200-day simple moving average is $23.69. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. Phreesia, Inc. has a 12-month low of $15.41 and a 12-month high of $32.76. The firm has a market capitalization of $1.03 billion, a PE ratio of -171.33 and a beta of 0.61.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.11. The company had revenue of $120.33 million for the quarter, compared to analysts’ expectations of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.Phreesia’s revenue was up 12.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.25) earnings per share. On average, research analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current year.

Institutional Investors Weigh In On Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the company. Moody National Bank Trust Division grew its holdings in Phreesia by 63.8% in the fourth quarter. Moody National Bank Trust Division now owns 195,944 shares of the company’s stock worth $3,315,000 after purchasing an additional 76,345 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Phreesia in the 4th quarter worth $1,203,000. Diversified Trust Co. grew its stake in Phreesia by 12.2% during the 4th quarter. Diversified Trust Co. now owns 51,422 shares of the company’s stock worth $870,000 after buying an additional 5,600 shares during the last quarter. Tudor Investment Corp ET AL purchased a new position in Phreesia during the 3rd quarter worth $4,173,000. Finally, FNY Investment Advisers LLC acquired a new position in Phreesia during the 3rd quarter valued at about $183,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on PHR shares. Citigroup lowered their price objective on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Friday. Zacks Research lowered shares of Phreesia from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Mizuho lowered their price target on shares of Phreesia from $36.00 to $28.00 and set an “outperform” rating for the company in a research report on Wednesday, December 10th. Needham & Company LLC reissued a “buy” rating and set a $35.00 price objective on shares of Phreesia in a report on Monday, December 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Phreesia in a research note on Friday, October 31st. Seventeen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Phreesia has a consensus rating of “Moderate Buy” and a consensus target price of $30.06.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.